Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · IEX Real-Time Price · USD
49.57
+0.31 (0.63%)
At close: Jul 19, 2024, 4:00 PM
49.55
-0.02 (-0.04%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 226 employees as of December 31, 2023. The number of employees increased by 49 or 27.68% compared to the previous year.
Employees
226
Change (1Y)
49
Growth (1Y)
27.68%
Revenue / Employee
$406,752
Profits / Employee
-$1,211,819
Market Cap
3.02B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 226 | 49 | 27.68% |
Dec 31, 2022 | 177 | 37 | 26.43% |
Dec 31, 2021 | 140 | 50 | 55.56% |
Dec 31, 2020 | 90 | 20 | 28.57% |
Dec 31, 2019 | 70 | 16 | 29.63% |
Dec 31, 2018 | 54 | 28 | 107.69% |
Dec 31, 2017 | 26 | 11 | 73.33% |
Dec 31, 2016 | 15 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
ICU Medical | 14,000 |
Envista Holdings | 12,800 |
Azenta | 3,500 |
LivaNova | 2,900 |
Oscar Health | 2,400 |
iRhythm Technologies | 2,000 |
ADMA Biologics | 624 |
ACADIA Pharmaceuticals | 598 |
RYTM News
- 10 days ago - Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewsWire
- 23 days ago - Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency - GlobeNewsWire
- 6 weeks ago - Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 - GlobeNewsWire
- 6 weeks ago - Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology - GlobeNewsWire
- 3 months ago - Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 - GlobeNewsWire